The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
Open accessAbstract
Purpose: Imatinib mesylate is a targeted agent that may be used against Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), one of the highest risk pediatric ALL groups. Patients and Methods: We evaluated whether imatinib (340 mg/m 2 /d) with an intensive chemotherapy regimen improved outcome in children ages 1 to 21 years with Ph+ ALL (N = 92) and compared toxicities to Ph− ALL patients (N = 65) given the same chemotherapy without imatinib. Exposure to imatinib was increased progressively in five patient cohorts that received imatinib from 42 (cohort 1; n = 7) to 280 continuous days (cohort 5; n = 50) before maintenance therapy. Patients with human leukocyte antigen (HLA) –identical sibling donors underwent blood and marrow transplantation (BMT) with imatinib given for 6 months following BMT. Results: Continuous imatinib exposure improved outcome in cohort 5 patients with a 3-year event-free survival (EFS) of 80% ± 11% (95% CI, 64% to 90%), more than twice historical controls (35% ± 4%; P < .0001). Three-year EFS was similar for patients in cohort 5 treated with chemotherapy plus imatinib (88% ± 11%; 95% CI, 66% to 96%) or sibling donor BMT (57% ± 22%; 95% CI, 30.4% to 76.1%). There were no significant toxicities associated with adding imatinib to intensive chemotherapy. The higher imatinib dosing in cohort 5 appears to improve survival by having an impact on the outcome of children with a higher burden of minimal residual disease after induction. Conclusion: Imatinib plus intensive chemotherapy improved 3-year EFS in children and adolescents with Ph+ ALL, with no appreciable increase in toxicity. BMT plus imatinib offered no advantage over BMT alone. Additional follow-up is required to determine the impact of this treatment on long-term EFS and determine whether chemotherapy plus imatinib can replace BMT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Treatment of Acute Lymphoblastic Leukemia
Pui, C.-H., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 1,976
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,344
Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1446 · Cited by 1,159
Imatinib Mesylate — A New Oral Targeted Therapy
Savage, D. G., & Antman, K. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmra013339 · Cited by 844
Borowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., Linda, S., Martin, P. L., Pullen, D. J., Viswanatha, D., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132837 · Cited by 842
Self-citationOutcome of Treatment in Children with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Aricò, M., Valsecchi, M. G., Camitta, B., Schrappe, M., Chessells, J., Baruchel, A., Gaynon, P., Silverman, L., Janka-Schaub, G., Kamps, W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004063421402 · Cited by 600
Self-citationThomas, D. A. (2004) · Blood · doi:10.1182/blood-2003-08-2958 · Cited by 571
Schultz, K. R., Pullen, D. J., Sather, H. N., Shuster, J. J., Devidas, M., Borowitz, M. J., Carroll, A. J., Heerema, N. A., Rubnitz, J. E., Loh, M. L., et al. (2007) · Blood · doi:10.1182/blood-2006-01-024729 · Cited by 475
Self-citationQuintás-Cardama, A., Kantarjian, H., O'Brien, S., Borthakur, G., Bruzzi, J., Munden, R., & Cortes, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0329 · Cited by 388
Ottmann, O., Dombret, H., Martinelli, G., Simonsson, B., Guilhot, F., Larson, R. A., Rege-Cambrin, G., Radich, J., Hochhaus, A., Apanovitch, A. M., et al. (2007) · Blood · doi:10.1182/blood-2007-02-073528 · Cited by 366
Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995
Gaynon, P., Trigg, M., Heerema, N., Sensel, M., Sather, H., Hammond, G., & Bleyer, W. (2000) · Leukemia · doi:10.1038/sj.leu.2401939 · Cited by 319
Self-citationCongestive heart failure is a rare event in patients receiving imatinib therapy
Atallah, E., Durand, J.-B., Kantarjian, H., & Cortes, J. (2007) · Blood · doi:10.1182/blood-2007-01-070144 · Cited by 252
Champagne, M. A., Capdeville, R., Krailo, M., Qu, W., Peng, B., Rosamilia, M., Therrien, M., Zoellner, U., Blaney, S. M., & Bernstein, M. (2004) · Blood · doi:10.1182/blood-2003-09-3032 · Cited by 238
Carpenter, P. A., Snyder, D., Flowers, M. E. D., Sanders, J. E., Gooley, T. A., Martin, P. J., Appelbaum, F. R., & Radich, J. P. (2006) · Blood · doi:10.1182/blood-2006-04-019836 · Cited by 226
STI571: A Paradigm of New Agents for Cancer Therapeutics
Mauro, M. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.325 · Cited by 202
Indications for Imatinib Mesylate Therapy and Clinical Management
Guilhot, F. (2004) · The Oncologist · doi:10.1634/theoncologist.9-3-271 · Cited by 190
STI571: A Paradigm of New Agents for Cancer Therapeutics
Mauro, M. J., O'Dwyer, M. E., Heinrich, M. C., & Druker, B. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.1.325 · Cited by 127
Maloney, K., Shuster, J. J., Murphy, S. B., Pullen, J., & Camitta, B. M. (2000) · Leukemia · doi:10.1038/sj.leu.2401965 · Cited by 105
Self-citationOverexpression of glut-1 glucose transporter in human breast cancer an immunohistochemical study
(1993) · doi:10.1002/1097-0142(19931115)72:10 · Cited by 1
Cited by
Acute Lymphoblastic Leukemia in Children
Hunger, S. P., & Mullighan, C. G. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1400972 · Cited by 2,204
Self-citationTargetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Roberts, K. G., Li, Y., Payne-Turner, D., Harvey, R. C., Yang, Y.-L., Pei, D., McCastlain, K., Ding, L., Lu, C., Song, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403088 · Cited by 1,377
Self-citationKinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Hunger, S. P., Lu, X., Devidas, M., Camitta, B. M., Gaynon, P. S., Winick, N. J., Reaman, G. H., & Carroll, W. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.8018 · Cited by 1,180
Self-citationInaba, H., Greaves, M., & Mullighan, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62187-4 · Cited by 1,074
Metadata
- Authors
- Schultz, K. R., Bowman, W. P., Aledo, A., Slayton, W. B., Sather, H., Devidas, M., Wang, C., Davies, S. M., Gaynon, P. S., Trigg, M., Rutledge, R., Burden, L., Jorstad, D., Carroll, A., Heerema, N. A., Winick, N., Borowitz, M. J., Hunger, S. P., Carroll, W. L., & Camitta, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-11-01
- Volume
- 27
- Issue
- 31
- Pages
- 5175-5181
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2096336184
- Cited by
- 701
- References
- 27
- FWCI
- 52.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.